Hypersensitivity, Immediate Recruiting Phase 2 Trials for Benralizumab (DB12023)

Also known as: Type I Hypersensitivity / Immediate Hypersensitivity / Hypersensitivity type I / Hypersensitivity type I NOS / Immediate hypersensitivity reaction

IndicationStatusPhase
DBCOND0031076 (Hypersensitivity, Immediate)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03563066Effect of Benralizumab in Atopic DermatitisTreatment